Global Healthcare Analyst

Tina Banerjee

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pyridam-farma-tbk-pt" target="_blank" data-smartkarma-citation="entities:12900:1" rel="noopener">Pyridam Farma (PYFA IJ)</a> is acquiring <a href="https://www.smartkarma.com/entities/probiotec-ltd" target="_blank" data-smartkarma-citation="entities:12047:1" rel="noopener">Probiotec Ltd (PBP AU)</a>, a leading contract manufacturer and packer of prescription and OTC pharmaceuticals, complementary medicines, consumer health products, and FMCG.  </li>
<li>Under the terms of the scheme, Probiotec shareholders will receive cash consideration of A$3.00 per share. This implies an equity value of ~A$251M for Probiotec and enterprise value of ~A$326M.</li>
<li>The acquisition will add an attractive high-margin revenue stream to Pyridam. Through the acquisition of Probiotec, Pyridam will be capable to reach a wider market, thereby increasing its market share.</li>
</ul>



Pyridam Farma (PYFA IJ) is acquiring Probiotec Ltd (PBP AU), a leading contract manufacturer and packer of prescription and OTC pharmaceuticals, complementary medicines, consumer health products, and FMCG.  
Under the terms of the scheme, Probiotec shareholders will receive cash consideration of A$3.00 per share. This implies an equity value of ~A$251M for Probiotec and enterprise value of ~A$326M.
The acquisition will add an attractive high-margin revenue stream to Pyridam. Through the acquisition of Probiotec, Pyridam will be capable to reach a wider market, thereby increasing its market share.


Pyridam Farma (PYFA IJ): Acquisition of Australian Contract Manufacturer to Add Long-Term Value

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

<ul>
<li>Back on the 21st Feb 2025, <a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener">Mayne Pharma (MYX AU)</a> entered into a Scheme with US-based pharmaceutical outfit, Cosette Pharmaceuticals, at A$7.40/share. The wheels fell off the deal shortly afterward.</li>
<li>Cosette issued a "material adverse change" notice concerning a FDA warning/notice (on Nextstellis®) and Mayne's earnings guidance.  The Supreme Court disagreed. Cosette appealed. The Court has now dismissed that appeal.</li>
<li>Cosette's concurrent threat to shut the Salisbury manufacturing plant lead to Treasurer Jim Chalmers blocking the deal last November. Thanks Jim. Absent your intervention, Cosette had no legal out.</li>
</ul>


Back on the 21st Feb 2025, Mayne Pharma (MYX AU) entered into a Scheme with US-based pharmaceutical outfit, Cosette Pharmaceuticals, at A$7.40/share. The wheels fell off the deal shortly afterward.
Cosette issued a "material adverse change" notice concerning a FDA warning/notice (on Nextstellis®) and Mayne's earnings guidance.  The Supreme Court disagreed. Cosette appealed. The Court has now dismissed that appeal.
Cosette's concurrent threat to shut the Salisbury manufacturing plant lead to Treasurer Jim Chalmers blocking the deal last November. Thanks Jim. Absent your intervention, Cosette had no legal out.


Mayne Pharma (MYX AU): This One's On You Jim As Court Dismisses Cosette's Appeal

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/pyridam-farma-tbk-pt">Pyridam Farma</a> is undergoing an aggressive, debt-fueled expansion, marked by a dramatic 173% revenue increase in FY24, primarily driven by the acquisitions of PT Holi Pharma, PT Ethica Industri Farmasi, and Australia-based Probiotec Ltd.</li>
 <li>This rapid top-line growth has come at a significant cost to profitability and cash flow, with the company posting substantial net losses and negative operating cash flow over the past three years, raising concerns about the sustainability of its strategy.</li>
 <li>Valuation appears stretched, trading at a significant premium to peers across key metrics, which reflects market optimism about its growth strategy but overlooks the considerable integration and execution risks ahead.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Pyridam Farma is undergoing an aggressive, debt-fueled expansion, marked by a dramatic 173% revenue increase in FY24, primarily driven by the acquisitions of PT Holi Pharma, PT Ethica Industri Farmasi, and Australia-based Probiotec Ltd.
  This rapid top-line growth has come at a significant cost to profitability and cash flow, with the company posting substantial net losses and negative operating cash flow over the past three years, raising concerns about the sustainability of its strategy.
  Valuation appears stretched, trading at a significant premium to peers across key metrics, which reflects market optimism about its growth strategy but overlooks the considerable integration and execution risks ahead.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Pyridam Farma (PYFA IJ) - Feb 2026

ASEAN Insight Provider, CrossASEAN Research

Angus Mackintosh

ASEAN Insight Provider

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Cross Asset Strategy

<ul>
<li>The Past week saw insights of <a href="https://www.smartkarma.com/entities/prodia-widyahusada" target="_blank" data-smartkarma-citation="entities:23663:1" rel="noopener">Prodia (PRDA IJ)</a>, <a href="https://www.smartkarma.com/entities/grab-holdings-ltd" target="_blank" data-smartkarma-citation="entities:26950:1" rel="noopener">Grab Holdings (GRAB US)</a>, <a href="https://www.smartkarma.com/entities/xl-axiata-tbk-pt" target="_blank" data-smartkarma-citation="entities:15028:1" rel="noopener">XL Axiata (EXCL IJ)</a>, <a href="https://www.smartkarma.com/entities/kalbe-farma-tbk-pt" target="_blank" data-smartkarma-citation="entities:6303:1" rel="noopener">Kalbe Farma (KLBF IJ)</a>, <a href="https://www.smartkarma.com/entities/bank-mandiri-persero-tbk-pt" target="_blank" data-smartkarma-citation="entities:441:1" rel="noopener">Bank Mandiri (BMRI IJ)</a>, and <a href="https://www.smartkarma.com/entities/pyridam-farma-tbk-pt" target="_blank" data-smartkarma-citation="entities:12900:1" rel="noopener">Pyridam Farma (PYFA IJ)</a>.</li>
<li>The was also an insight on <a href="https://www.smartkarma.com/entities/thonburi-healthcare-group-pcl" target="_blank" data-smartkarma-citation="entities:24386:1" rel="noopener">Thonburi Healthcare Group (THG TB)</a> and a sector piece looking at the beleaguered Vietnamese Real Estate sector. </li>
<li>The Week That Was in ASEAN@Smartkarma is filled with an eclectic mix of differentiated, substantive, and actionable insights, macro and equity bottom-up, from across Southeast Asia.</li>
</ul>


The Past week saw insights of Prodia (PRDA IJ), Grab Holdings (GRAB US), XL Axiata (EXCL IJ), Kalbe Farma (KLBF IJ), Bank Mandiri (BMRI IJ), and Pyridam Farma (PYFA IJ).
The was also an insight on Thonburi Healthcare Group (THG TB) and a sector piece looking at the beleaguered Vietnamese Real Estate sector. 
The Week That Was in ASEAN@Smartkarma is filled with an eclectic mix of differentiated, substantive, and actionable insights, macro and equity bottom-up, from across Southeast Asia.


The Week That Was in ASEAN@Smartkarma - Prodia's Recovery, Grab in 2024, and Kalbe Farma Primed

<ul>
<li>For November 2025, eight new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$10bn.</li>
<li>The average premium for the new transactions announced (or first discussed) in November was ~31%, with a year-to-date average of ~48%.</li>
<li>The average premiums for transactions in 2024 (129 transactions), 2023 (117), 2022 (106), 2021 (165), 2020 (158), and 2019 (145 ) were 43%, 39%, 41%, 33%, 31%, and 31%.</li>
</ul>


For November 2025, eight new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$10bn.
The average premium for the new transactions announced (or first discussed) in November was ~31%, with a year-to-date average of ~48%.
The average premiums for transactions in 2024 (129 transactions), 2023 (117), 2022 (106), 2021 (165), 2020 (158), and 2019 (145 ) were 43%, 39%, 41%, 33%, 31%, and 31%.


(Mostly) Asia M&A, Nov 2025 Wrap: Qube, Forum Engineering, National Storage REIT, Star Micronics

Indonesia

PT Pyridam Farma Tbk is an Indonesia-based pharmaceutical company that produces, develops, and trades pharmaceuticals, medical devices, and cosmetics. Its product portfolio includes prescription and over-the-counter drugs, vitamins, supplements, aesthetic products, and medical equipment. The company was founded in 1976 and is headquartered in Jakarta, Indonesia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pyridam Farma (PYFA IJ)